KRYS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
119.2M
+2.5%
116.4M
+8.6%
107.1M
+9.5%
97.8M
+1.8%
96.0M
Cost of Revenue
6.4M
+1.8%
6.3M
-4.1%
6.6M
+54.6%
4.3M
-40.5%
7.2M
Gross Profit
112.8M
+2.5%
110.0M
+9.5%
100.5M
+7.5%
93.5M
+5.2%
88.9M
Operating Expenses
54.4M
-3.5%
56.3M
+0.2%
56.2M
+7.8%
52.2M
+5.4%
49.5M
R&D
14.5M
-5.3%
15.3M
+3.6%
14.8M
+1.4%
14.6M
+1.2%
14.4M
SG&A
39.9M
-2.8%
41.0M
-1.0%
41.4M
+10.3%
37.6M
+7.2%
35.1M
Operating Income
58.4M
+8.8%
53.7M
+21.3%
44.3M
+7.0%
41.4M
+5.0%
39.4M
EBITDA
59.8M
+8.3%
55.2M
+20.5%
45.8M
+7.1%
42.8M
+5.0%
40.7M
Net Income
54.8M
-2.1%
55.9M
+8.8%
51.4M
-35.2%
79.4M
+107.0%
38.3M
EPS (Basic)
$1.85
-3.1%
$1.91
+7.9%
$1.77
-35.4%
$2.74
+106.0%
$1.33
EPS (Diluted)
$1.79
-2.2%
$1.83
+8.3%
$1.69
-36.5%
$2.66
+106.2%
$1.29
Shares (Diluted)
30.7M
+0.5%
30.5M
+0.5%
30.4M
+1.7%
29.8M
+0.3%
29.7M
Krystal Biotech (KRYS) โ€” Financials